Skip to main content

Advertisement

SpringerLink
Log in

Cellular immunotherapy for cancer. Past, present, future

  • editorial
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3:241–52.

    Article  CAS  PubMed  Google Scholar 

  2. Bortin MM, Rimm AA, Saltzstein EC. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science. 1973;179:811–3.

    Article  CAS  PubMed  Google Scholar 

  3. Mathe G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 1965;25:1525–31.

    CAS  PubMed  Google Scholar 

  4. Schwarzenberg L, Mathe G, Schneider M, et al. Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet. 1966;2:365–8.

    Article  CAS  PubMed  Google Scholar 

  5. Nadler SH, Moore GE. Immunotherapy of malignant disease. Arch Surg. 1969;99:376–81.

    Article  CAS  PubMed  Google Scholar 

  6. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.

    CAS  PubMed  Google Scholar 

  7. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–33.

    Article  CAS  PubMed  Google Scholar 

  8. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–14.

    CAS  PubMed  Google Scholar 

  9. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–62.

    CAS  PubMed  Google Scholar 

  10. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–5.

    CAS  PubMed  Google Scholar 

  11. Faber LM, Van Der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest. 1995;96:877–83.

    Article  CAS  PubMed  Google Scholar 

  12. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.

    Article  CAS  PubMed  Google Scholar 

  13. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–70.

    Article  CAS  PubMed  Google Scholar 

  14. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–45.

    Article  CAS  PubMed  Google Scholar 

  15. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–9.

    Article  CAS  PubMed  Google Scholar 

  16. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–41.

    Article  CAS  PubMed  Google Scholar 

  17. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958–67.

    Article  CAS  PubMed  Google Scholar 

  18. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.

    Article  CAS  PubMed  Google Scholar 

  19. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–8.

    Article  CAS  PubMed  Google Scholar 

  20. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37.

    Article  PubMed  Google Scholar 

  21. Gerdemann U, Katari U, Christin AS, et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011;19:2258–68.

    Article  CAS  PubMed  Google Scholar 

  22. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545–86.

    Article  CAS  PubMed  Google Scholar 

  23. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294–305.

    Article  CAS  PubMed  Google Scholar 

  24. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7.

    Article  CAS  PubMed  Google Scholar 

  25. Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972–85.

    Article  CAS  PubMed  Google Scholar 

  26. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.

    Article  CAS  PubMed  Google Scholar 

  27. Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179–87.

    Article  CAS  PubMed  Google Scholar 

  28. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.

    Article  CAS  PubMed  Google Scholar 

  29. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33:305–15.

    Article  CAS  PubMed  Google Scholar 

  30. Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9:214.

    Google Scholar 

Download references

Conflict of interest

The author declares that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Hematology Division, University Hospital of Patras, 26500, Rio, Patras, Greece

    Alexandros Spyridonidis MD, PhD

Authors
  1. Alexandros Spyridonidis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandros Spyridonidis MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spyridonidis, A. Cellular immunotherapy for cancer. Past, present, future. memo 5, 81–84 (2012). https://doi.org/10.1007/s12254-012-0023-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0023-2

Search

Navigation